Although psychedelic drugs can be thought of as dangerous and harmful, scientists have conducted experiments and clinical trials on some of them and achieved positive results by testing them for medical use. Studies have shown that drugs such as MDMA (a type of methamphetamine), LSD, and psilocybin (“magic mushrooms”) can be helpful in treating severe pain, anxiety, depression, and certain mental illnesses.
Successful outcomes have been achieved when psychedelics are used to treat conditions such as post-traumatic stress disorder and alcohol and smoking addiction, for example. In many cases, these treatments have been used by people who have unsuccessfully tried to treat their conditions with other methods.
Experts have warned, however, that treatments using psychedelic drugs must be administered in very carefully controlled conditions, with precise dose monitoring and administration as prescribed. A drug delivery system that can meet these needs would provide an obvious advantage over standard methods such as oral administration, injection, or topical and nasal delivery.
The Terasaki Institute for Biomedical Innovation (TIBI) offers a microneedle patch for drug delivery that can be fine-tuned for dosing and timing. The patch is made of a gelatinous substance and contains tiny microneedles on one surface that include a drug or combination of drugs for application. After application to the skin, microneedles penetrate the surface and then biodegrade, releasing their drug load under the surface in a controlled manner.
Researchers at TIBI have designed their microneedle patches for a variety of purposes, including drug delivery and gene and stem cell therapies. “Our microneedle technology enables the delivery of drugs and treatments in a safe, easy, painless and minimally invasive way,” said Dr. Ali Khademhosseini, Director and CEO of TIBI. ”It also enables supervised delivery, using materials that are highly biocompatible and biodegradable. “
TIBI recently partnered with Pharma Ther, Inc., to develop microneedle patches specifically for the delivery of psychedelic drugs for medical purposes. Pharma Ther is a special life sciences company focused on the research and development of psychedelic drugs; they will work with TIBI to develop patches for the use of their products in alternative treatment approaches.
“We are excited to work with the Terasaki Institute and the inventors of GelMA delivery technology, as it provides a solid foundation for product acceleration and clinical development for the first unique microdose dosing system to treat serious unmet medical needs,” said Fabio Chianelli, CEO of PharmaTher -a. “Our focus is the search for psychedelic prescription drugs for FDA and international regulatory approval and unlocking the potential therapeutic value of these compounds through TIBI microneedle patches.”
Terasaki Institute for Biomedical Innovation